KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Alnylam Pharmaceuticals (ALNY) Shares Outstanding (2016 - 2026)

Alnylam Pharmaceuticals (ALNY) has disclosed Shares Outstanding for 18 consecutive years, with $133.4 million as the latest value for Q1 2026.

  • For Q1 2026, Shares Outstanding rose 2.4% year-over-year to $133.4 million; the TTM value through Mar 2026 reached $133.4 million, up 2.4%, while the annual FY2025 figure was $132.4 million, 2.38% up from the prior year.
  • Shares Outstanding hit $133.4 million in Q1 2026 for Alnylam Pharmaceuticals, up from $132.4 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $133.4 million in Q1 2026 and bottomed at $120.7 million in Q1 2022.
  • Average Shares Outstanding over 5 years is $127.1 million, with a median of $126.5 million recorded in 2024.
  • On a YoY basis, Shares Outstanding climbed as much as 3.23% in 2023 and fell as far as 1.51% in 2023.
  • Alnylam Pharmaceuticals' Shares Outstanding stood at $123.9 million in 2022, then increased by 1.51% to $125.8 million in 2023, then increased by 2.78% to $129.3 million in 2024, then rose by 2.38% to $132.4 million in 2025, then grew by 0.81% to $133.4 million in 2026.
  • According to Business Quant data, Shares Outstanding over the past three periods came in at $133.4 million, $132.4 million, and $131.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.